The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Wellvone     3-[4-(4- chlorophenyl)cyclohexyl]-4- hydroxy...

Synonyms: Malarone, ATOVAQUONE, Acuvel, Mepron, pron, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Mepron


High impact information on Mepron


Chemical compound and disease context of Mepron


Biological context of Mepron


Anatomical context of Mepron


Associations of Mepron with other chemical compounds


Gene context of Mepron

  • Atovaquone inhibits the bc1 complex competitively with apparent Ki = 9 nm, raises the midpoint potential of the Rieske iron-sulfur protein from 285 to 385 mV, and shifts the g values in the EPR spectrum of the Rieske center [23].
  • No synergy could be demonstrated between atovaquone and DHFR inhibitors or macrolides [27].
  • Using uptake of 3H-vinblastine in L-MDR1 cells, atovaquone was shown to inhibit P-glycoprotein with an apparent Ki of 95.6 microM [28].
  • CONCLUSIONS: Atovaquone is a relatively weak inhibitor of CYP2C9-mediated SMX-HA formation in vitro [29].
  • RESULTS: No in vitro atovaquone resistance (IC50 > 1900 nM) and no cytb mutation leading to the Y268S substitution were detected among 477 unexposed African P. falciparum isolates [30].

Analytical, diagnostic and therapeutic context of Mepron


  1. A preliminary evaluation of 566C80 for the treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome. Falloon, J., Kovacs, J., Hughes, W., O'Neill, D., Polis, M., Davey, R.T., Rogers, M., LaFon, S., Feuerstein, I., Lancaster, D. N. Engl. J. Med. (1991) [Pubmed]
  2. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. El-Sadr, W.M., Murphy, R.L., Yurik, T.M., Luskin-Hawk, R., Cheung, T.W., Balfour, H.H., Eng, R., Hooton, T.M., Kerkering, T.M., Schutz, M., van der Horst, C., Hafner, R. N. Engl. J. Med. (1998) [Pubmed]
  3. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lell, B., Luckner, D., Ndjavé, M., Scott, T., Kremsner, P.G. Lancet (1998) [Pubmed]
  4. Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The NIAID-Clinical Center Intramural AIDS Program. Kovacs, J.A. Lancet (1992) [Pubmed]
  5. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team. Høgh, B., Clarke, P.D., Camus, D., Nothdurft, H.D., Overbosch, D., Günther, M., Joubert, I., Kain, K.C., Shaw, D., Roskell, N.S., Chulay, J.D. Lancet (2000) [Pubmed]
  6. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Atovaquone Study Group. Dohn, M.N., Weinberg, W.G., Torres, R.A., Follansbee, S.E., Caldwell, P.T., Scott, J.D., Gathe, J.C., Haghighat, D.P., Sampson, J.H., Spotkov, J., Deresinski, S.C., Meyer, R.D., Lancaster, D.J. Ann. Intern. Med. (1994) [Pubmed]
  7. Cytochrome b mutations that modify the ubiquinol-binding pocket of the cytochrome bc1 complex and confer anti-malarial drug resistance in Saccharomyces cerevisiae. Kessl, J.J., Ha, K.H., Merritt, A.K., Lange, B.B., Hill, P., Meunier, B., Meshnick, S.R., Trumpower, B.L. J. Biol. Chem. (2005) [Pubmed]
  8. Uncovering the molecular mode of action of the antimalarial drug atovaquone using a bacterial system. Mather, M.W., Darrouzet, E., Valkova-Valchanova, M., Cooley, J.W., McIntosh, M.T., Daldal, F., Vaidya, A.B. J. Biol. Chem. (2005) [Pubmed]
  9. Atovaquone and proguanil for Plasmodium falciparum malaria. Radloff, P.D., Philipps, J., Nkeyi, M., Hutchinson, D., Kremsner, P.G. Lancet (1996) [Pubmed]
  10. Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. Lee, B.L., Täuber, M.G., Sadler, B., Goldstein, D., Chambers, H.F. Clin. Pharmacol. Ther. (1996) [Pubmed]
  11. The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine. Araujo, F.G., Lin, T., Remington, J.S. J. Infect. Dis. (1993) [Pubmed]
  12. Synergistic effect of clindamycin and atovaquone in acute murine toxoplasmosis. Djurković-Djaković, O., Nikolić, T., Robert-Gangneux, F., Bobić, B., Nikolić, A. Antimicrob. Agents Chemother. (1999) [Pubmed]
  13. Atovaquone and proguanil for the treatment of malaria in Brazil. de Alencar, F.E., Cerutti, C., Durlacher, R.R., Boulos, M., Alves, F.P., Milhous, W., Pang, L.W. J. Infect. Dis. (1997) [Pubmed]
  14. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. Srivastava, I.K., Rottenberg, H., Vaidya, A.B. J. Biol. Chem. (1997) [Pubmed]
  15. Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. Hussein, Z., Eaves, J., Hutchinson, D.B., Canfield, C.J. Clin. Pharmacol. Ther. (1997) [Pubmed]
  16. Recapitulation in Saccharomyces cerevisiae of cytochrome b mutations conferring resistance to atovaquone in Pneumocystis jiroveci. Hill, P., Kessl, J., Fisher, N., Meshnick, S., Trumpower, B.L., Meunier, B. Antimicrob. Agents Chemother. (2003) [Pubmed]
  17. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Korsinczky, M., Chen, N., Kotecka, B., Saul, A., Rieckmann, K., Cheng, Q. Antimicrob. Agents Chemother. (2000) [Pubmed]
  18. Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group. Katlama, C., Mouthon, B., Gourdon, D., Lapierre, D., Rousseau, F. AIDS (1996) [Pubmed]
  19. Successful prevention and treatment of babesiosis with atovaquone. Hughes, W.T., Oz, H.S. J. Infect. Dis. (1995) [Pubmed]
  20. Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis. Dunay, I.R., Heimesaat, M.M., Bushrab, F.N., Müller, R.H., Stocker, H., Arasteh, K., Kurowski, M., Fitzner, R., Borner, K., Liesenfeld, O. Antimicrob. Agents Chemother. (2004) [Pubmed]
  21. Disposition of atovaquone in humans. Rolan, P.E., Mercer, A.J., Tate, E., Benjamin, I., Posner, J. Antimicrob. Agents Chemother. (1997) [Pubmed]
  22. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. Hughes, W., Leoung, G., Kramer, F., Bozzette, S.A., Safrin, S., Frame, P., Clumeck, N., Masur, H., Lancaster, D., Chan, C. N. Engl. J. Med. (1993) [Pubmed]
  23. Molecular basis for atovaquone binding to the cytochrome bc1 complex. Kessl, J.J., Lange, B.B., Merbitz-Zahradnik, T., Zwicker, K., Hill, P., Meunier, B., Pálsdóttir, H., Hunte, C., Meshnick, S., Trumpower, B.L. J. Biol. Chem. (2003) [Pubmed]
  24. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. Goldie, S.J., Kaplan, J.E., Losina, E., Weinstein, M.C., Paltiel, A.D., Seage, G.R., Craven, D.E., Kimmel, A.D., Zhang, H., Cohen, C.J., Freedberg, K.A. Arch. Intern. Med. (2002) [Pubmed]
  25. Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe. Wichmann, O., Muehlberger, N., Jelinek, T., Alifrangis, M., Peyerl-Hoffmann, G., Muhlen, M., Grobusch, M.P., Gascon, J., Matteelli, A., Laferl, H., Bisoffi, Z., Ehrhardt, S., Cuadros, J., Hatz, C., Gjorup, I., McWhinney, P., Beran, J., da Cunha, S., Schulze, M., Kollaritsch, H., Kern, P., Fry, G., Richter, J. J. Infect. Dis. (2004) [Pubmed]
  26. Pharmacokinetics of azithromycin administered alone and with atovaquone in human immunodeficiency virus-infected children. The ACTG 254 Team. Ngo, L.Y., Yogev, R., Dankner, W.M., Hughes, W.T., Burchett, S., Xu, J., Sadler, B., Unadkat, J.D. Antimicrob. Agents Chemother. (1999) [Pubmed]
  27. In-vitro activity of atovaquone, sulphamethoxazole and dapsone alone and combined with inhibitors of dihydrofolate reductase and macrolides against Pneumocystis carinii. Cirioni, O., Giacometti, A., Scalise, G. J. Antimicrob. Chemother. (1997) [Pubmed]
  28. The effect of atovaquone on etoposide pharmacokinetics in children with acute lymphoblastic leukemia. van de Poll, M.E., Relling, M.V., Schuetz, E.G., Harrison, P.L., Hughes, W., Flynn, P.M. Cancer Chemother. Pharmacol. (2001) [Pubmed]
  29. Inhibition by atovaquone of CYP2C9-mediated sulphamethoxazole hydroxylamine formation. Miller, J.L., Trepanier, L.A. Eur. J. Clin. Pharmacol. (2002) [Pubmed]
  30. Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers. Musset, L., Pradines, B., Parzy, D., Durand, R., Bigot, P., Le Bras, J. J. Antimicrob. Chemother. (2006) [Pubmed]
  31. Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients. Dixon, R., Pozniak, A.L., Watt, H.M., Rolan, P., Posner, J. Antimicrob. Agents Chemother. (1996) [Pubmed]
  32. Pneumocystis carinii cytochrome b mutations are associated with atovaquone exposure in patients with AIDS. Kazanjian, P., Armstrong, W., Hossler, P.A., Lee, C.H., Huang, L., Beard, C.B., Carter, J., Crane, L., Duchin, J., Burman, W., Richardson, J., Meshnick, S.R. J. Infect. Dis. (2001) [Pubmed]
  33. Pneumocystis carinii pneumonia prophylaxis with atovaquone in trimethoprim-sulfamethoxazole-intolerant orthotopic liver transplant patients: a preliminary study. Meyers, B., Borrego, F., Papanicolaou, G. Liver Transpl. (2001) [Pubmed]
WikiGenes - Universities